Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Details on the poster presentations are below:
Title: Tegoprubart for the prevention of rejection in kidney transplant: update of emerging data from an ongoing trial
Poster Number: TH-PO835
Session Title: Transplantation: Clinical - I [PO2102-1]
Session Date and Time:
Following the presentation, a copy of the poster can be found on the Investor section of the Company’s website at https://ir.eledon.com/events-and-presentations/presentations.
About Eledon Pharmaceuticals and Tegoprubart (formerly AT-1501)
Eledon Pharmaceuticals is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organs, as well as to treat amyotrophic lateral sclerosis (ALS). The Company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand (also called “CD154”), a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine,
(858) 525 2047
Berry & Company Public Relations
(212) 253 8881
Source: Eledon Pharmaceuticals
Source: Eledon Pharmaceuticals, Inc.